NEW ANALYSIS PROVIDES ADDITIONAL SUPPORT FOR CRT THERAPY FOR PATIENTS WITH HEART FAILURE

Data presented Sept. 5 at the European Society of Cardiology/World Congress of Cardiology shows that long-term use of cardiac resynchronisation therapy (CRT) or CRT-D (with an implantable cardioverter defibrillator) is a cost-effective method of increasing survival in patients with heart failure, according to Medtronic.

"The CARE-HF study provides conclusive evidence that, for patients with moderate or severe heart failure, CRT is a treatment that both improves symptoms and reduces mortality, a finding that is further supported by a meta-analysis of reported studies," said John Cleland, chairman of the Cardiac Resynchronization in Heart Failure steering committee and head of the Department of Cardiology, Castle Hill Hospital, Kingston-upon-Hill, United Kingdom.